| Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer RK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, ... New England Journal of Medicine 382 (7), 597-609, 2020 | 1234 | 2020 |
| Sacituzumab govitecan in metastatic triple-negative breast cancer A Bardia, SA Hurvitz, SM Tolaney, D Loirat, K Punie, M Oliveira, A Brufsky, ... New England journal of medicine 384 (16), 1529-1541, 2021 | 1207 | 2021 |
| Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma L De Mattos-Arruda, R Mayor, CKY Ng, B Weigelt, F Martínez-Ricarte, ... Nature communications 6 (1), 8839, 2015 | 803 | 2015 |
| Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with≥ 2 HER2-directed regimens: phase III NALA trial C Saura, M Oliveira, YH Feng, MS Dai, SW Chen, SA Hurvitz, SB Kim, ... Journal of Clinical Oncology 38 (27), 3138-3149, 2020 | 540 | 2020 |
| Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind … SB Kim, R Dent, SA Im, M Espié, S Blau, AR Tan, SJ Isakoff, M Oliveira, ... The Lancet Oncology 18 (10), 1360-1372, 2017 | 529 | 2017 |
| Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial NU Lin, V Borges, C Anders, RK Murthy, E Paplomata, E Hamilton, ... Journal of Clinical Oncology 38 (23), 2610-2619, 2020 | 482 | 2020 |
| Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle L De Mattos-Arruda, B Weigelt, J Cortes, HH Won, CKY Ng, P Nuciforo, ... Annals of oncology 25 (9), 1729-1735, 2014 | 423 | 2014 |
| HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer … A Llombart-Cussac, J Cortés, L Paré, P Galván, B Bermejo, N Martínez, ... The lancet oncology 18 (4), 545-554, 2017 | 356 | 2017 |
| Capivasertib in hormone receptor–positive advanced breast cancer NC Turner, M Oliveira, SJ Howell, F Dalenc, J Cortes, HL Gomez Moreno, ... New England Journal of Medicine 388 (22), 2058-2070, 2023 | 352 | 2023 |
| Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer A Bardia, SM Tolaney, K Punie, D Loirat, M Oliveira, K Kalinsky, A Zelnak, ... Annals of Oncology 32 (9), 1148-1156, 2021 | 252 | 2021 |
| Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label … A Prat, C Saura, T Pascual, C Hernando, M Muñoz, L Paré, BG Farré, ... The lancet oncology 21 (1), 33-43, 2020 | 182 | 2020 |
| A first-in-human phase I study of the ATP-competitive AKT inhibitor ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumors C Saura, D Roda, S Roselló, M Oliveira, T Macarulla, JA Pérez-Fidalgo, ... Cancer discovery 7 (1), 102-113, 2017 | 176 | 2017 |
| Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries SR Knight, CA Shaw, R Pius, TM Drake, L Norman, AO Ademuyiwa, ... The Lancet 397 (10272), 387-397, 2021 | 165 | 2021 |
| FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer M Oliveira, C Saura, P Nuciforo, I Calvo, J Andersen, JL Passos-Coelho, ... Annals of Oncology 30 (8), 1289-1297, 2019 | 146 | 2019 |
| HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade A Prat, T Pascual, C De Angelis, C Gutierrez, A Llombart-Cussac, T Wang, ... JNCI: Journal of the National Cancer Institute 112 (1), 46-54, 2020 | 144 | 2020 |
| Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial S Hrebien, V Citi, I Garcia-Murillas, R Cutts, K Fenwick, I Kozarewa, ... Annals of Oncology 30 (6), 945-952, 2019 | 137 | 2019 |
| Neratinib+ capecitabine versus lapatinib+ capecitabine in patients with HER2+ metastatic breast cancer previously treated with≥ 2 HER2-directed regimens: Findings from the … C Saura, M Oliveira, YH Feng, MS Dai, SA Hurvitz, SB Kim, B Moy, ... Journal of Clinical Oncology 37 (15_suppl), 1002-1002, 2019 | 135 | 2019 |
| Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative P Aftimos, M Oliveira, A Irrthum, D Fumagalli, C Sotiriou, EN Gal-Yam, ... Cancer discovery 11 (11), 2796-2811, 2021 | 133 | 2021 |
| Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain … NU Lin, RK Murthy, V Abramson, C Anders, T Bachelot, PL Bedard, ... JAMA oncology 9 (2), 197-205, 2023 | 118 | 2023 |
| Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI … C Saura, D Hlauschek, M Oliveira, D Zardavas, A Jallitsch-Halper, ... The Lancet Oncology 20 (9), 1226-1238, 2019 | 110 | 2019 |
